Medrio Enhances RTSM For Faster Clinical Trial Starts and Greater Flexibility

SAN FRANCISCO, March 26, 2025 /PRNewswire/ -- Medrio, a global leader in clinical trial technology, today announced enhancements to its randomization and trial supply management (RTSM) solution. This latest release delivers faster implementation, greater flexibility, and enhanced self-service capabilities.

"Our customers need RTSM to be as agile as the trials they run," said Nicole Latimer, Chief Executive Officer at Medrio. "By expanding our configurability capabilities, we're allowing teams to build, test, and deploy Medrio RTSM in a fraction of the time of traditional systems without relying on extensive vendor support."

The latest IRT Benchmarking & Market Dynamics (5th Ed.) report cites that 77% of clinical trials now require moderate to high-complexity RTSM builds. This finding highlights the need for flexible and configurable RTSM systems. Designed in collaboration with customers, Medrio RTSM eliminates the barriers and complexity of traditional vendor-dependent setups. With no-code configurability, sponsors and CROs can build and deploy in weeks, not months.

"The Medrio RTSM build team has been great to work with, showing knowledge, professionalism, flexibility, and the ability to meet study timelines," said Kenneth Homer, Director of Biostatistics and Programming at Homer Biometrics, LLC.  "I am looking forward to Medrio releasing their front end, allowing us to configure the RTSM system on demand. This will be invaluable in helping us meet the needs of our clients."

Medrio RTSM seamlessly integrates with the Medrio CDMS/EDC platform to deliver a unified trial management experience. This connectivity eliminates data silos, reduces reconciliation efforts, and ensures real-time data synchronization. Automated supply management, point-and-click configurability, and mid-study adaptability allow teams to adjust to protocol changes quickly while maintaining oversight and control.

This latest evolution underscores Medrio's commitment to advancing clinical trial efficiency. Recent innovations, including AI-enabled reporting, further streamline operations and reduce study timelines. By removing barriers to speed and usability, Medrio ensures that research teams can focus on delivering high-quality data while accelerating trial execution.

Medrio RTSM is available now, with expanded self-service functionality rolling out throughout 2025. Customers can also leverage Medrio's tiered enablement packages and expert support to optimize their RTSM workflows.

Request a demo today to see how Medrio can help you accelerate timelines, reduce complexity, and take full control of your trial execution.

About Medrio
Trusted by sponsors, CROs, and sites worldwide, Medrio aims to improve 100 million lives through faster, more efficient, and secure clinical trials. With almost two decades of experience, Medrio delivers proven, scalable solutions, unrivaled customer support, and guidance to the industry's leading innovators, including pharmaceutical, biotech, medical device, diagnostics and more. The company's suite of solutions, including CDMS/EDC, eCOA/ePRO, eConsent and RTSM, enables the capture of quality clinical trial data while optimizing workflows for regulatory readiness. Experience the power of Medrio and realize the full potential of your clinical operations and outcomes.

Contacts
Dana Perotti
Medrio
[email protected]

SOURCE Medrio